In vitro model of Kaposi's sarcoma (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vitro model of Kaposi's sarcoma (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A3237 1993. Unique Identifier : AIDSLINE ICDB/93694193
Moyer MP; Cantu AA; Anderson LS; Torres R; Cagle MP; Jenson HB; Univ. of Texas Health Science Center, San Antonio, TX 78284.

Abstract: Primary cultures of human submucosal mesenchymal (SM) cells from the intestine infected with the human immunodeficiency virus (HIV) displayed Kaposi's sarcoma (KS)-like changes in growth and morphology. More IL-6 was released from HIV-infected than control cultures at early times (3-6 days postinfection) even though virus replication did not occur. In long-term studies (weeks to months) persistent or latent virus was sometimes detected, as were shifts in specific markers of angioblast/endothelial cells. Angiogenesis studies of culture supernatants were positive. Similar effects on cell growth and cytokine induction were found upon transfection of the HIV tat gene into the SM cells. This is a good in vitro model that demonstrates cytokine induction of a KS phenotype, differentiation of endothelial and mesenchymal cells, and angiogenesis.
Keywords: Cells, Cultured Gene Products, tat/GENETICS Human HIV/PHYSIOLOGY Interleukin-6/METABOLISM Intestines/CYTOLOGY/MICROBIOLOGY Neovascularization, Pathologic Sarcoma, Kaposi's/METABOLISM/MICROBIOLOGY/*PATHOLOGY Transfection Virus Replication ABSTRACTKWDcells,culturedgeneproducts,tat/geneticshumanhiv/physiologyinterleukin-6/metabolismintestines/cytology/microbiologyneovascularization,pathologicsarcoma,kaposi's/metabolism/microbiology/KWDpathologytransfectionvirusreplicationabstract
931230
M93C0807

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .